Published • loading... • Updated
Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List
- Innovent Biologics announced that seven innovative products were included in China’s updated 2026 National Reimbursement Drug List .
- Mazdutide, PECONDLE®, TABOSUN®, and Vanflyta® entered the NRDL for the first time.
- TYVYT® and Jaypirca® received coverage for new indications, while SINTBILO® was renewed.
- The updated NRDL takes effect on January 1, 2027, expanding Innovent’s covered innovative-drug lineup to 17 products.
Insights by Ground AI
27 Articles
27 Articles
Napa Valley Register+26 Reposted by 26 other sources
Innovent Announces Seven Innovative Products Including Mazdutide and PECONDLE® Successfully Included in the 2026 National Reimbursement Drug List
PALO ALTO, Calif. and SUZHOU, China, Nov. 14, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and…
Coverage Details
Total News Sources27
Leaning Left2Leaning Right1Center21Last UpdatedBias Distribution88% Center
Bias Distribution
- 88% of the sources are Center
88% Center
C 88%
Factuality
To view factuality data please Upgrade to Premium
